• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    1/26/24 8:05:58 AM ET
    $ACON
    $AIMD
    $ARAV
    $CRBP
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Inspire Veterinary (NASDAQ:IVP) stock moved upwards by 178.9% to $0.52 during Friday's pre-market session. The company's market cap stands at $5.7 million.
    • Aclarion (NASDAQ:ACON) stock increased by 115.01% to $4.01. The company's market cap stands at $3.3 million.
    • Panbela Therapeutics (NASDAQ:PBLA) stock increased by 61.23% to $5.24. The market value of their outstanding shares is at $2.5 million.
    • Corbus Pharmaceuticals (NASDAQ:CRBP) stock rose 25.48% to $10.59. The company's market cap stands at $46.8 million.
    • NeuBase Therapeutics (NASDAQ:NBSE) shares rose 20.92% to $0.75. The company's market cap stands at $2.7 million.
    • Ainos (NASDAQ:AIMD) shares moved upwards by 19.07% to $1.18. The company's market cap stands at $5.5 million.

    Losers

    • Onconetix (NASDAQ:ONCO) stock decreased by 32.8% to $0.23 during Friday's pre-market session. The market value of their outstanding shares is at $5.0 million.
    • Jin Medical International (NASDAQ:ZJYL) stock fell 18.52% to $224.99. The market value of their outstanding shares is at $1.7 billion.
    • Passage Bio (NASDAQ:PASG) shares declined by 11.09% to $0.81. The market value of their outstanding shares is at $44.4 million.
    • PTC Therapeutics (NASDAQ:PTCT) stock decreased by 9.98% to $24.0. The market value of their outstanding shares is at $1.8 billion.
    • Aravive (NASDAQ:ARAV) shares declined by 8.86% to $0.04. The company's market cap stands at $3.1 million.
    • Sagimet Biosciences (NASDAQ:SGMT) stock decreased by 8.71% to $12.8. The market value of their outstanding shares is at $293.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AIMD
    $ARAV
    $CRBP

    CompanyDatePrice TargetRatingAnalyst
    Passage Bio Inc.
    $PASG
    2/10/2026$21.00Buy
    Chardan Capital Markets
    Sagimet Biosciences Inc.
    $SGMT
    2/3/2026$27.00Buy
    Guggenheim
    Sagimet Biosciences Inc.
    $SGMT
    1/28/2026$8.00Equal Weight
    Barclays
    PTC Therapeutics Inc.
    $PTCT
    1/28/2026$119.00Overweight
    Barclays
    PTC Therapeutics Inc.
    $PTCT
    12/1/2025$91.00Outperform → Sector Perform
    RBC Capital Mkts
    PTC Therapeutics Inc.
    $PTCT
    10/20/2025$73.00Overweight
    Wells Fargo
    Sagimet Biosciences Inc.
    $SGMT
    8/11/2025$28.00Outperform
    Wedbush
    Sagimet Biosciences Inc.
    $SGMT
    8/7/2025$29.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACON
    $AIMD
    $ARAV
    $CRBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EXEC. VP AND CLO Boulding Mark Elliott sold $209,763 worth of shares (3,019 units at $69.48), decreasing direct ownership by 3% to 105,212 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    2/23/26 5:20:05 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF BUSINESS OFFICER Pauwels Eric sold $209,398 worth of shares (3,019 units at $69.36), decreasing direct ownership by 4% to 77,122 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    2/20/26 5:20:11 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $511,253 worth of shares (7,371 units at $69.36), decreasing direct ownership by 2% to 387,082 units (SEC Form 4)

    4 - PTC THERAPEUTICS, INC. (0001070081) (Issuer)

    2/20/26 5:20:09 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AIMD
    $ARAV
    $CRBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets resumed coverage on Passage BIO with a new price target

    Chardan Capital Markets resumed coverage of Passage BIO with a rating of Buy and set a new price target of $21.00

    2/10/26 6:56:48 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on Sagimet Biosciences with a new price target

    Guggenheim initiated coverage of Sagimet Biosciences with a rating of Buy and set a new price target of $27.00

    2/3/26 7:59:13 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Sagimet Biosciences with a new price target

    Barclays initiated coverage of Sagimet Biosciences with a rating of Equal Weight and set a new price target of $8.00

    1/28/26 7:18:50 AM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AIMD
    $ARAV
    $CRBP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ness Brent bought $62 worth of shares (10 units at $6.20), increasing direct ownership by 1,000% to 11 units (SEC Form 4)

    4 - Aclarion, Inc. (0001635077) (Issuer)

    12/1/25 5:00:02 PM ET
    $ACON
    Medical Specialities
    Health Care

    Large owner Lynx1 Capital Management Lp bought $2,261 worth of shares (325 units at $6.96) and bought $221,474 worth of shares (31,683 units at $6.99) (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    9/15/25 8:05:45 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Lynx1 Capital Management Lp bought $662,488 worth of shares (115,725 units at $5.72) and bought $71,338 worth of shares (13,123 units at $5.44) (SEC Form 4)

    4 - Passage BIO, Inc. (0001787297) (Issuer)

    7/24/25 6:12:54 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AIMD
    $ARAV
    $CRBP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PTC Therapeutics to Participate at Upcoming Investor Conferences

    WARREN, N.J., Feb. 23, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) today announced that its executives will speak at the following conferences: TD Cowen 46th Annual Health Care Conference 2026Monday, March 2 at 9:50 a.m. ETLeerink 2026 Global Healthcare ConferenceTuesday, March 10 at 4:20 p.m. ETBarclays Global Healthcare Conference 2026Wednesday, March 11 at 8 a.m. ETThe presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived f

    2/23/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Full-year 2025 product and royalty revenue of $831M, exceeding guidance –– Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively –– Cash of $1.95B as of December 31, 2025 –WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.  "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs,

    2/19/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Passage Bio to Participate in Upcoming Investor Conferences

    PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Thursday, February 26, 2026Presentation Time: 8:40 a.m. ETLocation: Virtual TD Cowen 46th Annual Health Care ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Wednesday, March 4, 2026Presentation Time: 1:50 p.m. ETLocation:

    2/19/26 7:00:00 AM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AIMD
    $ARAV
    $CRBP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 14, 2024 - FDA Approves First Gene Therapy for Treatment of Aromatic L-amino Acid Decarboxylase Deficiency

    For Immediate Release: November 14, 2024 The U.S. Food and Drug Administration approved Kebilidi (eladocagene exuparvovec-tneq), an adeno-associated virus vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. Kebilidi is the first FDA-approved gene therapy for treatment of AADC deficiency. “Clinical advancements in the f

    11/14/24 8:50:18 AM ET
    $CLPT
    $PTCT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ACON
    $AIMD
    $ARAV
    $CRBP
    SEC Filings

    View All

    SEC Form 10-K filed by PTC Therapeutics Inc.

    10-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    2/19/26 4:36:19 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PTC THERAPEUTICS, INC. (0001070081) (Filer)

    2/19/26 4:14:13 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by PTC Therapeutics Inc.

    144 - PTC THERAPEUTICS, INC. (0001070081) (Subject)

    2/18/26 5:12:39 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AIMD
    $ARAV
    $CRBP
    Leadership Updates

    Live Leadership Updates

    View All

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

    PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (NASDAQ:PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage card

    12/1/25 9:00:00 AM ET
    $CVKD
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sandisk Set to Join S&P 500; Upwork, First Interstate BancSystem, PTC Therapeutics to Join S&P SmallCap 600

    NEW YORK, Nov. 24, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P SmallCap 600:  S&P SmallCap 600 constituent Sandisk Corp. (NASD: SNDK) will replace The Interpublic Group of Companies Inc. (NYSE:IPG) in the S&P 500, and PTC Therapeutics Inc. (NASD: PTCT) will replace Sandisk in the S&P SmallCap 600 effective prior to the opening of trading on Friday, November 28. S&P 500 constituent Omnicom Group Inc. (NYSE:OMC) is acquiring The Interpublic Group of Companies in a deal expected to close soon, pending final conditions.Upwork Inc. (NASD: UPWK) will replace Premier Inc. (NASD: PINC) in the S&P SmallCap 600 effective prior to the open of trading

    11/24/25 6:01:00 PM ET
    $FIBK
    $GIL
    $HBI
    Major Banks
    Finance
    Apparel
    Consumer Discretionary

    $ACON
    $AIMD
    $ARAV
    $CRBP
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

    – Full-year 2025 product and royalty revenue of $831M, exceeding guidance –– Strong Sephience™ (sepiapterin) uptake since 2H 2025 launch with fourth quarter and 2025 revenue of $92M and $111M, respectively –– Cash of $1.95B as of December 31, 2025 –WARREN, N.J., Feb. 19, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ:PTCT) today announced a corporate update and financial results for the fourth quarter and full year ending December 31, 2025.  "We delivered another strong quarter and finish to 2025, building on the successful global launch of Sephience," said Matthew B. Klein, M.D., Chief Executive Officer of PTC Therapeutics. "With our robust commercial engine, innovative R&D programs,

    2/19/26 4:01:00 PM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

    WARREN, N.J., Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year 2025 financial results and provide an update on the company's business and outlook on Thursday, Feb. 19, 2026, at 4:30 p.m. ET. To access the call by phone, please click here to register and you will be provided with dial-in details. The webcast conference call can be accessed on the Investors section of the PTC website at https://ir.ptcbio.com/events-presentations. A replay of the call w

    2/5/26 8:00:00 AM ET
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

    CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of 2.9% was observed at Day 14 in a dedicated cohort of people with obesity (n=12)A 12-week dose-finding study in people with obesity initiated with completion expected in summer 2026Company to host conference call and live webcast today at 8:00 am ET NORWOOD, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP), a clinical-stage company focused on oncology and obesity, today announced the completion of the single ascending dose (SAD) and multiple ascending d

    12/11/25 7:00:00 AM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AIMD
    $ARAV
    $CRBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Ainos Inc.

    SC 13D/A - Ainos, Inc. (0001014763) (Subject)

    11/27/24 6:08:44 AM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sagimet Biosciences Inc.

    SC 13G/A - Sagimet Biosciences Inc. (0001400118) (Subject)

    11/14/24 7:55:59 PM ET
    $SGMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

    SC 13G/A - Corbus Pharmaceuticals Holdings, Inc. (0001595097) (Subject)

    11/14/24 7:48:14 PM ET
    $CRBP
    Biotechnology: Pharmaceutical Preparations
    Health Care